Severe atopic dermatitis and concurrent severe hidradenitis suppurativa successfully treated with dupilumab

Min Kyung Cho; Jung U Shin; Dong Hyun Kim; Hee Jung Lee

doi:10.1111/ced.15387

Severe atopic dermatitis and concurrent severe hidradenitis suppurativa successfully treated with dupilumab

Clin Exp Dermatol. 2022 Dec;47(12):2303-2305. doi: 10.1111/ced.15387. Epub 2022 Sep 23.

Authors

Min Kyung Cho¹, Jung U Shin¹, Dong Hyun Kim¹, Hee Jung Lee¹

Affiliation

¹ Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.

PMID: 36006169
DOI: 10.1111/ced.15387

Abstract

We report a clinical experience of treating concomitant atopic dermatitis and hidradenitis suppurativa (HS) with dupilumab. This report is particularly noticeable in terms of disease severity and treatment duration compared to previous reported cases, suggesting long-term dupilumab therapy can contribute to disease control even in patients with severe HS.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Dermatitis, Atopic* / chemically induced
Dermatitis, Atopic* / complications
Dermatitis, Atopic* / drug therapy
Hidradenitis Suppurativa* / chemically induced
Hidradenitis Suppurativa* / complications
Hidradenitis Suppurativa* / drug therapy
Humans
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
Antibodies, Monoclonal, Humanized